The molecular subtypes (ER+/luminal, HER2, and basal-like) established in a landmark paper in 2000, redefined our understanding of breast cancer in terms of a tumour genotype/phenotype that could explain differences in clinical presentation and treatment response, and inform prognosis [7, 8]. Here, ESR1 is linked to neoplasm.